The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I:

##STR00001##

and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I: ##STR00001##
and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I: ##STR00001##
and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I:

##STR00001##

and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I:

##STR00001##

and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.